• Quotes

    GET QUOTE

    Enter Symbol:   

    Finance Center | MarketWatch

    CALCULATOR
  • Shortcuts

    LINKS

    INDUSTRIES

  • Login

    LOGIN

    Username:

    Password:

      

    Remember Login  

  • Amazon 
     
The Executive's Internet
Mon, Feb 23rd
US National News icon US NATIONAL NEWS | disclaimer | more news
NY Post National News: Senate Dems move to force Trump admin to pay back $175B in tariff refunds with new bill
icon
GoogleAmazonWikipedia
international news icon INTERNATIONAL NEWS | disclaimer | more news
News: Ford says 'walls closing in' on Trump after SCOTUS strikes down tariffs
Technology News icon TECHNOLOGY NEWS | disclaimer | more news
CNET Most Popular Products: What to Expect From Apple's March Event: New iPhones, iPads and MacBooks Expected Next Week
spacerspacer
Home
News News
Search Search
Industries Industries
CEO at Home Icon CEO@Home
Execudiva High Heel Shoe Execudiva
shopping cart Shop

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
My Headlines

Top News
   BUSINESS/FINANCE NEWS
Searching for 'drug'. (Return)

Inc.comFeb 23, 2026
Novo Nordisk's New Weight-Loss Drug Just Failed a Big Trial—So Why Is It Still Headed to Market?
The Danish drugmaker's latest trial setback intensifies its high-stakes rivalry with Eli Lilly in the booming obesity market.



RELATED ARTICLES
Novo Nordisk shares drop 15% after poor trial results for new obesity drug (FT.com - Financial Markets)

Google Market NewsFeb 23, 2026
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen - CNBC
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen  CNBCLilly to launch multi-dose weight-loss drug device in US  Yahoo FinanceLilly adds multidose Zepbound pens to self-pay menu after FDA nod  Fierce PharmaDiabetes Dialogue: Launch of the Zepbound KwikPen  HCPLive

Inc.comFeb 23, 2026
Eli Lilly's New $299 Month-Long GLP-1 Injector Shows Why It's Winning the Weight-Loss Race
The drugmaker is introducing a new, more convenient way to inject its blockbuster obesity drug, Zepbound.



RELATED ARTICLES
Novo Nordisk's stock slips to four-year low after its next-gen weight-loss drug lost to Lilly's in Phase 3 trial (MarketWatch)
TRENDING TAGS
Trumptariffs tariff Live updates CNBC
TariffTrump Live futures global updates
TariffsTrump Live updates CNBC Dow
GlobalTrump tariff trade Dow slides
SupremeCourt Trump tariffs wake Ruling
TargetPrice Buy Morgan Rating Stanley
liveupdates Trump CNBC Tariffs Dow
drugNovo Nordisk Lilly Eli trial
updatesLive Trump CNBC tariffs Dow
StocksBuy Trump higher gold tariff

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • c/o CommunityScape | 200 Anderson Avenue
    Rochester, NY 14607
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.
©1999-2026 CEOExpress Company LLC
Copyright & Disclaimer  |  Privacy Policy  |  Terms & Conditions